Five biomarkers improve risk assessment for adverse outcomes in ischemic stroke patients

Takeaway

  • Considering levels of high-sensitivity C-reactive protein (hsCRP), complement C3, matrix metalloproteinase-9 (MMP-9), hepatocyte growth factor (HGF), and antiphosphatidylserine antibodies (aPS) in addition to established stroke risk factors could significantly improve risk assessment for adverse outcomes in ischemic stroke patients.

Why this matters